Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Reuters

昨天

Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603964177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603964177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603964177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603964177","market":"nz","top_or_hot":-1,"title":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESNT.UK","symbol_name":"ESSENTRA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL2xNlQ5:1","article_id":"2603964177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603964177","pubTimestamp":1768557954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill cartridges, and LTS Device Technologies' Sorrel Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESNT.UK":"ESSENTRA","STVN":"Stevanato Group S.p.A.","BK4121":"生命科学工具和服务","BK5031":"商品化工","BK4539":"次新股"},"translate_title":"Stevanato Group与Datwyler和LTS Device Technologies合作扩展自我递送药物解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESNT.UK":0.9,"STVN":0.9},"content_text":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    \n\nStevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}